Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9gallium 68 PSMA-11 7Specimen Handling 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Standard of Care 2Radiation 2Positron Emission Tomography Computed Tomography 2HhAntag691 2Abiraterone Acetate 268Ga-DKFZ-PSMA-11 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2xentuzumab 1trastuzumab biosimilar HLX02 1tislelizumab 1teprotumumab 1tazemetostat 1relugolix 1pertuzumab 1palbociclib 1olaparib 1niraparib 1gallium citrate 1eribulin 1entrectinib 1darolutamide 1cobimetinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Prostatic Neoplasms × Lutetium × Clear all
NCT06516510 2025-09-25

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Blue Earth Therapeutics Ltd

Phase EARLY_PHASE1 Terminated
17 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡